Abilify (aripiprazole) vs Seroquel (quetiapine)
Abilify and Seroquel, compared on what the public record actually supports: side effects by rate from each FDA label, what the largest trial comparison found, who takes each one, who pays, what the labels warn, and what the litigation record holds. Sources on every number.
the short answer
- is Abilify or Seroquel more effective? there is no head-to-head trial record in our library that settles this pair, and we do not fill the gap with a guess. what can be compared is below: each label's own side-effect table, who takes each drug, who pays, and the legal record.
- which has fewer side effects? the labels say their trials “cannot be directly compared”, because each drug was tested in different people under different rules. what each label prints: Abilify (aripiprazole): the label prints no discontinuation rate in the section we transcribed. Seroquel (quetiapine): 4% stopped for an adverse reaction vs 3% on placebo (Seroquel label, SPL version 53, effective 2026-04-10). the reactions both labels list, side by side, are in the table below.
- which should i take? not a question this page answers. the odds ratios are averages across thousands of strangers; your history, other medications and what you can live with are not in them. the questions for your prescriber below are built from what is on this page.
What this page will not do is rank them. For most same-class pairs, head-to-head efficacy differences are smaller than the rankings look — the largest network meta-analysis ever run (21 antidepressants, 522 trials) found every drug beat placebo and the gaps between drugs mostly modest and uncertain. Which one fits you turns on your history, your other medications, and side-effect trade-offs — a prescriber conversation. This page arms that conversation; here are the questions worth taking into it →
side effects by rate: what each label prints, not a head-to-head trial
the labels' own warning, first: “Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.” the two columns below come from different trials, in different people, under different inclusion rules. read each against its own placebo column, not against the other drug.
| reaction | ABILIFY (n=1,843) vs Placebo (n=1,166) | SEROQUEL (n=719) vs PLACEBO (n=404) |
|---|---|---|
| dry mouth | 5% vs 4% | 9% vs 3% |
| constipation | 11% vs 7% | 8% vs 3% |
| somnolence | 5% vs 3% | 18% vs 8% |
| dizziness | 10% vs 7% | 11% vs 5% |
| headache | 27% vs 23% | 21% vs 14% |
| anxiety | 17% vs 13% | 4% vs 3% |
| agitation | 19% vs 17% | 20% vs 17% |
| vomiting | 11% vs 6% | 6% vs 5% |
| dyspepsia | 9% vs 7% | 5% vs 1% |
- Abilify (aripiprazole): the label prints no discontinuation rate in the section we transcribed.
- Seroquel (quetiapine): 4% stopped for an adverse reaction vs 3% on placebo (Seroquel label, SPL version 53, effective 2026-04-10).
what makes each table, in the labels' words
- Abilify (aripiprazole), SPL version 73, effective 2025-01-29, 6 ADVERSE REACTIONS / 6.1 Clinical Trials Experience, tablets, for oral use. inclusion rule: “Table 15 enumerates the pooled incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy (up to 6 weeks in schizophrenia and up to 3 weeks in bipolar mania), including only those reactions that occurred in 2% or more of patients treated with ABILIFY (doses ≥2 mg/day) and for which the incidence in patients treated with ABILIFY was greater than the incidence in patients treated with placebo in the combined dataset.” trials: “ABILIFY has been evaluated for safety in 13,543 adult patients who participated in multiple-dose, clinical trials in schizophrenia, bipolar disorder, major depressive disorder, dementia of the Alzheimer's type, Parkinson's disease, and alcoholism, and who had approximately 7,619 patient-years of exposure to oral ABILIFY and 749 patients with exposure to aripiprazole injection. A total of 3,390 patients were treated with oral ABILIFY for at least 180 days and 1,933 patients treated with oral ABILIFY had at least one year of exposure.” DailyMed
- Seroquel (quetiapine), SPL version 53, effective 2026-04-10, 6 ADVERSE REACTIONS / 6.1 Clinical Study Experience, immediate-release tablets (SEROQUEL); SEROQUEL XR extended-release is a separate label, not used here. inclusion rule: “Table 9 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy of schizophrenia (up to 6 weeks) and bipolar mania (up to 12 weeks) in 2% or more of patients treated with SEROQUEL (doses ranging from 75 to 800 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients.” trials: “The information below is derived from a clinical trial database for SEROQUEL consisting of over 4300 patients. This database includes 698 patients exposed to SEROQUEL for the treatment of bipolar depression, 405 patients exposed to SEROQUEL for the treatment of acute bipolar mania (monotherapy and adjunct therapy), 646 patients exposed to SEROQUEL for the maintenance treatment of bipolar I disorder as adjunct therapy, and approximately 2600 patients and/or normal subjects exposed to 1 or more doses of SEROQUEL for the treatment of schizophrenia.” DailyMed
every row above was transcribed from the current FDA label on 2026-09-08; the full tables, including the reactions only one label lists, are on side-effect rates, drug vs placebo. the sexual side-effect rows carry each label's own underreporting caveat on the SSRI sexual side effects page.
aripiprazole (Abilify)
atypical antipsychotic
- FDA approval
- 2002 · full approval journey →
- Who takes it (US, 2024)
- 1,780,154 patients · 8,246,932 prescriptions (AHRQ MEPS)2014 → 2024: 6,520,071 → 8,246,932 prescriptions; the change is within the survey’s margin of errorCorrection (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It said prescriptions were up 26% since 2014; that change is within the survey’s margin of error, so we no longer state a direction.
- Who pays (2024)
- Medicare: 4,109,192 claims · 683,829 beneficiariesMedicaid: ≥4,973,266 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →125,626 all-time reports; most-reported terms: off label use, drug ineffective, weight increased
- Legal & safety record
- the full litigation & recall record →
quetiapine (Seroquel)
atypical antipsychotic
- FDA approval
- 1997 · full approval journey →
- Who takes it (US, 2024)
- 1,849,066 patients · 8,669,046 prescriptions (AHRQ MEPS)2014 → 2024: 11,456,968 → 8,669,046 prescriptions; the change is within the survey’s margin of errorCorrection (29 September 2026): An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It said prescriptions were down 24% since 2014; that change is within the survey’s margin of error, so we no longer state a direction.
- Who pays (2024)
- Medicare: 9,859,922 claims · 1,488,315 beneficiariesMedicaid: ≥6,033,466 prescriptionsCommercial claims: not published in any public dataset — a real absence, not a zero.
- Boxed warning
- Yes — on the current FDA label. read it in context →
- Adverse-event reports (FAERS)
- Caveat first: FAERS counts unverified REPORTS, not patients or rates — no denominator, and attention inflates reporting. Never compare these counts head-to-head; a longer-marketed, more-prescribed drug accumulates more reports by exposure alone. how to read FAERS →191,484 all-time reports; most-reported terms: drug ineffective, off label use, toxicity to various agents
- Legal & safety record
- the full litigation & recall record →
questions for your prescriber, built from this page
this page does not tell you to start, stop or switch anything. it arms the conversation where that decision belongs. take these in:
- which of Abilify and Seroquel did you have in mind first, and what in my history points that way?
- the trials put these two close together on average. what, for me specifically, breaks the tie: another medication i take, a side effect i can't live with, sleep, weight, sexual function?
- the label lists these reactions above placebo for the one you're suggesting. which of them should i expect in the first weeks, and which would make you want to hear from me the same day?
- how long were the approval trials, and what do we know past that point?
- how will we judge whether it is working, by when, and what is the plan if it isn't?
- if i ever want to come off it, how is that done, and over how long?
- is there a cheaper generic or a formulation that changes the dosing, and does my insurance prefer one of these two?
the longer checklist, for any antidepressant, is questions to ask before starting antidepressants. if you are already on one and it feels like it stopped working, that has its own page.
What the warnings mean, drug by drug
Each explainer reads one drug's current FDA label and the studies in our library, in both directions: the boxed warnings with the label's own numbers, the trials behind the approval and how long they ran, side effects by rate, and the research since.
Questions people search
Is Abilify or Seroquel better?
No honest page can answer that in one line. Head-to-head differences between comparable psychiatric medications are usually smaller than rankings suggest, and which fits you depends on your history, other medications, and side-effect trade-offs, a prescriber conversation. What can be compared is the public record (usage, payers, label warnings, approval history, litigation), which is what this page does, with sources.
Is Abilify the same as aripiprazole, and Seroquel the same as quetiapine?
Abilify is a brand name for aripiprazole. Seroquel is a brand name for quetiapine. aripiprazole is an atypical antipsychotic; quetiapine is an atypical antipsychotic. This page uses the generic names because the federal datasets do.
Which has fewer side effects, Abilify or Seroquel?
The two FDA labels cannot be compared head to head, in their own words, because each drug's trials ran in different people under different rules. What each label prints: Abilify (aripiprazole): the label prints no discontinuation rate in the section we transcribed. Seroquel (quetiapine): 4% stopped for an adverse reaction vs 3% on placebo (Seroquel label, SPL version 53, effective 2026-04-10). The page shows the reactions both labels list, each against its own placebo column.
Which is prescribed more, Abilify or Seroquel?
The page shows federal survey estimates we compute from AHRQ’s Medical Expenditure Panel Survey public-use files for both aripiprazole and quetiapine: patients and prescriptions in the latest reliable year, and the yearly series from 2014 where AHRQ’s reliability rule allows it, with a direction stated only when the change is larger than the survey’s margin of error. Prescription volume reflects habits, prices, and marketing as much as evidence, so it is context, not a verdict.
Where these numbers come from
- Patients and prescriptions: computed by us from AHRQ's public-use Medical Expenditure Panel Survey Prescribed Medicines files, 2014 (HC-168A) to 2024 (HC-254A), with AHRQ's reliability rule (a year with fewer than 60 respondents or a relative standard error over 50% is not shown) — counts of people filling prescriptions, not outcomes. A direction is stated only when the change is larger than the survey's margin of error. Until 29 September 2026 these came from ClinCalc DrugStats, a third-party site; see the correction under each drug where a figure changed.
- Medicare/Medicaid: CMS public datasets; commercial insurance publishes no per-drug series, so it renders as an absence, never a synthesized number.
- Label facts: the drugs' current FDA labels via DailyMed — quoted in context on each drug's approval-journey page.
- FAERS: openFDA — reports, never rates; the caveat travels above every count.
- Litigation: court records and regulator documents only, on the linked record pages; settled is never adjudicated.
Explore both drugs in depth: /m/aripiprazole · /m/quetiapine · or the whole library →